IWP
VRTX icon

IAG Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

IAG Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50
Closed -$14K – 487
2022
Q3 		$14K Hold
50
– – ﹤0.01% 242
2022
Q2 		$14K Hold
50
– – ﹤0.01% 241
2022
Q1 		$13K Hold
50
– – ﹤0.01% 272
2021
Q4 		$11K Buy
+50
New +$9.72K ﹤0.01% 292
2020
Q3 		– Sell
-5
Closed -$2K – 434
2020
Q2 		$2K Hold
5
– – ﹤0.01% 374
2020
Q1 		$2K Hold
5
– – ﹤0.01% 359
2019
Q4 		$2K Buy
+5
New +$1.01K ﹤0.01% 396

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

IAG Wealth Partners's VRTX Position: Q4 2022 in Review

IAG Wealth Partners sold out of Vertex Pharmaceuticals (VRTX) in Q4 2022, closing a stake of 50 shares — an estimated $14K sold.

IAG Wealth Partners first reported a position in VRTX in Q4 2019 and held it in 7 quarters. The position peaked at $14K in Q3 2022. 1,223 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

  • IAG Wealth Partners reported no remaining Vertex Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • IAG Wealth Partners sold 50 Vertex Pharmaceuticals shares in Q4 2022, an estimated $14K.
  • IAG Wealth Partners first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 7 quarters.
  • IAG Wealth Partners's Vertex Pharmaceuticals position peaked at $14K in Q3 2022.
  • 1,223 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on IAG Wealth Partners's 13F filing for Q4 2022, filed 8 Feb 2023.